Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 9/20 | 0.57 |
| ▸ | MET | P08581 | 10/20 | 0.55 |
| ▸ | KDR | P35968 | 4/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | MERTK | Q12866 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456691 | 0.86 | MET (0.52) | AXLMETKDRPDGFRBHDAC2 | |
| SCHEMBL166914 | 0.82 | AXL (0.67) | AXLMETKDRPDGFRBKIT | |
| Hydrochloric Acid SCHEMBL21776567 | 0.81 | AXL (0.66) | AXLMETKDRPDGFRBKIT | |
| Hydrochloric Acid SCHEMBL30388215 | 0.81 | AXL (0.66) | AXLMETKDRPDGFRBKIT | |
| SCHEMBL17035605 | 0.81 | AXL (0.66) | AXLMETKDRPDGFRBKIT | |
| SCHEMBL29168479 | 0.81 | AXL (0.64) | AXLMETKDRPDGFRBHDAC2 | |
| SCHEMBL2063349 | 0.80 | KDR (0.75) | AXLMETKDRPDGFRBHDAC2 | |
| SCHEMBL17035604 | 0.80 | AXL (0.64) | AXLMETKDRPDGFRBKIT | |
| SCHEMBL20032554 | 0.80 | AXL (0.68) | AXLMETKDRPDGFRBFLT3 | |
| SCHEMBL2101280 | 0.80 | KDR (0.62) | AXLMETKDRPDGFRBRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513283-B2 | Spiro substituted compounds as angiogenesis inhibitors | ADVENCHEN LABORATORIES, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2125777-B1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LAB LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120165371-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2012-06-28 | — | — | US | disclosed |
| US-8163923-B2 | Benzyl 1-((6-methoxy-4-(5-(methylcarbamoyl)naphthalen-2-yloxy)quinolin-7-yloxy)methyl)cyclo-propylcarbamate; cancers associated with protein tyrosine kinases | ADVENCHEN LABORATORIES, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2125777-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | Advenchen Laboratories, LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | ADVENCHEN LABORATORIES, LLC | 2008-09-18 | — | — | US | disclosed |
| WO-2008112408-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | ADVENCHEN LABORATORIES, LLC (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165371-A1 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | TEK, KDR, TIE1 | AXL 65/4885MET 176/4885KDR 2/4885 |
| US-20080227812-A1 | Spiro Substituted Compounds As Angiogenesis Inhibitors | TEK, KDR, TIE1 | AXL 65/4885MET 176/4885KDR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.